AI assistant
CAMBRIDGE NUTRITIONAL SCIENCES PLC Report Publication Announcement 2021
7544_dva_2021-11-05_6cac70e5-ddac-40e9-b767-4c0052df3193.html
Report Publication Announcement
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information 
RNS Number : 4182R
Omega Diagnostics Group PLC
05 November 2021
OMEGA DIAGNOSTICS GROUP PLC
("Omega" or the "Company" or the "Group")
Notice of Results
Investor Presentation
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, announces it will release its interim results for the six months ended 30 September 2021 on Thursday 25 November 2021.
Investor presentation
Colin King, CEO, and Chris Lea, CFO, will provide a live presentation relating to the Interim Results via the Investor Meet Company platform on 25 November 2021 at 4:30pm GMT.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet OMEGA DIAGNOSTICS GROUP PLC via:
https://www.investormeetcompany.com/omega-diagnostics-group-plc/register-investor
Investors who already follow OMEGA DIAGNOSTICS GROUP PLC on the Investor Meet Company platform will automatically be invited.
Contacts:
| Omega Diagnostics Group PLC | www.omegadx.com | |
| Colin King, Chief Executive | via Walbrook PR | |
| Chris Lea, Chief Financial Officer | ||
| finnCap Ltd | Tel: 020 7220 0500 | |
| Geoff Nash/Edward Whiley (Corporate Finance) | ||
| Alice Lane/ Charlotte Sutcliffe (ECM) | ||
| Walbrook PR Limited | Tel: 020 7933 8780 or [email protected] | |
| Paul McManus | Mob: 07980 541 893 | |
| Lianne Applegarth | Mob: 07584 391 303 | |
| Sam Allen | Mob: 07502 558 258 | |
About Omega Diagnostics Group PLC
Omega manufactures and distributes high quality in-vitro diagnostic products for use in hospitals, clinics, laboratories and healthcare practitioners in over 75 countries and specialise in the areas of health and nutrition and global health.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NORFSLFMLEFSEIF